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Background: T-cell intracellular antigen (TIA) proteins function as regulators of cell homeostasis. These proteins
control gene expression globally at multiple levels in response to dynamic regulatory changes and environmental
stresses. Herein we identified a micro(mi)RNA signature associated to transiently TIA-depleted HeLa cells and
analyzed the potential role of miRNAs combining genome-wide analysis data on mRNA and miRNA profiles.
Results: Using high-throughput miRNA expression profiling, transient depletion of TIA-proteins in HeLa cells was
observed to promote significant and reproducible changes affecting to a pool of up-regulated miRNAs involving
miR-30b-3p, miR125a-3p, miR-193a-5p, miR-197-3p, miR-203a, miR-210, miR-371-5p, miR-373-5p, miR-483-5p, miR-492,
miR-498, miR-503-5p, miR-572, miR-586, miR-612, miR-615-3p, miR-623, miR-625-5p, miR-629-5p, miR-638, miR-658,
miR-663a, miR-671-5p, miR-769-3p and miR-744-5p. Some up-regulated and unchanged miRNAs were validated
and previous results confirmed by reverse transcription and real time PCR. By target prediction of the miRNAs and
combined analysis of the genome-wide expression profiles identified in TIA-depleted HeLa cells, we detected
connections between up-regulated miRNAs and potential target genes. Gene Ontology (GO) and Kyoto
Encyclopedia of Genes and Genomes (KEGG) database analysis suggest that target genes are related with
biological processes associated to the regulation of DNA-dependent transcription, signal transduction and
multicellular organismal development as well as with the enrichment of pathways involved in cancer, focal
adhesion, regulation of actin cytoskeleton, endocytosis and MAPK and Wnt signaling pathways, respectively. When
the collection of experimentally defined differentially expressed genes in TIA-depleted HeLa cells was intersected
with potential target genes only 7 out of 68 (10%) up- and 71 out of 328 (22%) down-regulated genes were
shared. GO and KEGG database analyses showed that the enrichment categories of biological processes and
cellular pathways were related with innate immune response, signal transduction, response to interleukin-1,
glomerular basement membrane development as well as neuroactive ligand-receptor interaction, endocytosis,
lysosomes and apoptosis, respectively.
Conclusion: All this considered, these observations suggest that individual miRNAs could act as potential
mediators of the epigenetic switch linking transcriptomic dynamics and cell phenotypes mediated by TIA proteins.
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Nowadays, the central dogma of Molecular Biology —
developed from classic research works aimed at determin-
ing the biology of prokaryotic organisms— is known to
reflect only a part of the agenda containing the genetic
information that gives rise to the complexity of eukaryotic
organisms. The characterization of post-transcriptional
events leading to the generation of multiple RNAs, pro-
teins and functions from only one RNA precursor shows
up the existence of multiple overlapping regulatory net-
works and mechanisms for the control of biological func-
tions beyond transcriptional regulation. There is increasing
evidence to support the idea that transcriptome and
proteome regulation and heterogeneity are key stages to
understand differences in the protein diversity observed
in organisms of similar genetic complexity. It’s therefore
necessary to fully characterize the modulators linking and
synchronizing multiple layers of gene expression regulation.
T-cell intracellular antigen 1 (TIA1) and TIA1 related/
like (TIAR/TIAL1) proteins are two DNA/RNA binding
proteins that regulate many aspects of RNA metabolism
at different levels. These multifunctional regulators can
modulate: i) DNA-dependent transcription through its
interaction with DNA and RNA polymerase II [1-4]; ii)
alternative splicing of pre-mRNA through the selection
of atypical 50 spliced sites [5-8], and iii) stability and/or
translation of eukaryotic mRNAs through the interaction
with 50 and/or 30 untranslatable regions [9-16]. Some of
these regulatory layers operate in the control of main
biological programmes so as to maintain cellular homeo-
stasis; this programmes include apoptosis, inflammation,
cell responses to stress or viral infections ([10] and refer-
ences included). Furthermore, mice lacking either TIA1
[16] or TIAR [17], as well as ectopically over-expressing
TIAR [18], show higher rates of embryonic lethality.
MicroRNAs (miRNAs) are a class of 19-25 nt long
non-coding RNAs that regulate post-transcriptionally
gene expression by binding with partially complemen-
tary sequences on target mRNAs and inhibiting transla-
tion or affecting stability of these mRNAs [19]. Multiple
lines of evidence indicate that they are key regulators of
numerous critical functions in developmental, cell dif-
ferentiation and disease processes, including tumorigen-
esis and cancer progression [19]. However, defining the
place and function of miRNAs in complex regulatory
networks is not straightforward. Systems’ approaches
such as the inference of a module network from expres-
sion data can help to achieve this goal [19].
We have previously described specific changes of tran-
scriptomic dynamics associated to inflammation, angiogen-
esis, metabolism, and cell proliferation-related genes upon
TIA1/TIAR-RNA interference-based silencing in HeLa cells
[10]. In the present study, we test the hypothesis whether
there are specific changes associated to the pattern ofmiRNA expression which may interfere/modulate with
target genes and, therefore, contribute to the phenotypes
described in TIA-depleted HeLa cells. Herein, we identi-
fied a miRNA signature that is concomitant and coherent
with biological processes and pathways associated to the
phenotypes observed in HeLa cells lacking TIA proteins.
Methods
Cell culture and RNA interference (RNAi)analysis
HeLa cells were grown and transfected with 20 nM of
either a control siRNA (non-silencing siRNA duplex
fluorescein labeled 27-6411-02FL from Gene Link) or
two siRNAs against TIA1 (50-AAGCTCTAATTCTGCAA
CTCTTT-30; 50-AACAACTAA TGCGTCAGACTTTT-30)
and TIAR (50-AAGTCCTTATACTTCAGTTGTTC-30; 50-
AACCATGGAATCAACAAGGATTT-30) directed to the
positions 59-81/647-669 and 65-87/971-993 to the cod-
ing regions of TIA1 and TIAR mRNAs, respectively, as
described previously [7,10].
Cell extract preparation, western blot analysis and RNA
purification
Whole-cell extracts were prepared by resuspensing the
cells in lysis buffer (50 mM Tris–HCl, pH 8.0, 140 mM
NaCl, 1.5 mM MgCl2, 0.5% Nonidet P-40 plus a mixture
of protease inhibitors), freeze-thawing three times, and
centrifugation at 10,000 rpm for 5 min. in a microfuge
at 4°C. Resulting supernatants were recovered and stored
at -70°C [10]. Immunoblots were carried out loading
equal amounts of protein (15 μg) on 10% SDS-PAGE
and using the following antibodies: anti-TIA1 and anti-
TIAR from Santa Cruz Biotechnology (CA, USA) and
anti-α-tubulin from Sigma (UK). RNA was extracted by
using a miRVANA kit (Ambion, TX, USA) according to
the manufacturer’s protocol.
MicroRNA expression profiling analysis
The quality of the total RNA was verified by an Agilent
2100 Bioanalyzer profile. 2000 ng total RNA from each
sample was labeled with Hy3™ or Hy5™ fluorescent label,
using the miRCURY LNA™ microRNA Labeling Kit
Hy3™/Hy5™ (Exiqon, Denmark), following the proced-
ure described by the manufacturer. A Hy3™- and a
Hy5™-labeled RNA sample were mixed pair-wise and
hybridized to the miRCURY LNA™ microRNA Array
(Exiqon, Denmark), which contains capture probes tar-
geting all microRNAs for human registered in the miR-
BASE version 9.1. The hybridization was performed
according to the miRCURY LNA™ microRNA Array In-
struction manual using a Tecan HS4800™ hybridization
station (Tecan, Austria). After hybridization the micro-
array slides were scanned and stored in an ozone free en-
vironment (ozone level below 2.0 ppb) in order to prevent
potential bleaching of the fluorescent dyes. The miRCURY
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Agilent G2565BA Microarray Scanner System (Agilent
Technologies, Inc., USA) and the image analysis was
carried out using the ImaGeneW 7.0 (miRCURY LNA™
microRNA Array Analysis Software, Exiqon, Denmark).
The quantified signals were background corrected (local
background subtraction) and normalized using the glo-
bal Lowess (LOcally WEighted Scatterplot Smoothing)
regression algorithm.
Local background was corrected by normexp method
with an offset of 50. Background corrected intensities were
transformed to log scale (base 2) and normalized by Low-
ess for each array [20]. Finally, to have similar intensity
distribution across all arrays, Lowess-normalized-intensity
values were scaled by adjusting their quantiles [21]. After
data processing each probe was tested for changes in
expression over replicates using an empirical Bayes mod-
erated t statistic [22]. To control the false discovery rate
(FDR), P values were corrected using the method of
Benjamini and Hochberg (1995) [23]. FIESTA viewer
(http://bioinfogp.cnb.csic.es/tools/ FIESTA) was used to
visualize all microarray results and to evaluate the nu-
merical thresholds (-2> fold change >2; FDR < 0.0001)
applied for selecting differentially expressed genes [24].
The miRPlus sequences are licensed human sequences
(Exiqon, Denmark). Some of them are already annotated
in the miRBase database version 18. Microarray data
discussed in this publication have been deposited in the
NCBI Gene Expression Omnibus database (http://www.
ncbi.nlm.nih.gov/geo/info/linking.html) and are access-
ible through the GEO Series accession number GSE41213.
QPCR
The method was optimized for microRNA, and reagents,
primers, and probes were obtained from Applied Biosys-
tems. Reverse transcriptase (RT) reactions and real-time
PCR (PCR) were performed according to manufacturer
protocols at the Genomic PCR Core Facility at Universidad
Autónoma de Madrid in Madrid Scientific Park. Analyses
were performed in two independent samples by triplicate,
including no-template and RT-minus controls. U6 RNA
and miR-200 expression were used as endogenous refer-
ence controls. Relative miRNA expression was calculated
using the comparative cycle threshold method.
Generation of miRNA targets dataset
In silico targets predicted for each of the differentially
expressed miRNAs by three different algorithms: TargetS-
can 5.2 ([25] and references included), PicTar-Vert ([26]
and references included) and miRDB [27,28] were down-
loaded using web-app miRBase [29] (http://www.mirbase.
org). Given that each algorithm focus on different aspects
of miRNA-mRNA pairing, and the lack of experimental
validation of most miRNAs targets do not allow a false-positive elimination, we kept the datasets by considering
the following score values: TargetScan 5.2 (aggregate
PCT > 0.1), PicTar-Vert (PicTar score > 2) and miRBD
(target score > 70).
Gene ontology, pathway and network analyses
The Gene Ontology (GO) and Kyoto Encyclopedia of
Genes and Genomes (KEGG) database analysis were con-
ducted using software programmes provided by GenCodis3
(http://genecodis.cnb.csic.es) [30,31]. Networks and regu-
latory topologies of functional relationships between gene
clusters were created using the CytoScape [32] (http://www.
cytoscape.org).
Results
To analyze the putative role of TIA proteins in the control
of gene expression on microRNAs, we transfected HeLa
cells with double-stranded small interfering RNAs (siRNAs)
targeting TIA1 and TIAR mRNAs or with control siRNA
(C), as previously reported [10]. The effect of siRNAs on
TIA1/TIAR expression was analyzed by Western blotting
(Figure 1A). Upon TIA1/TIAR-RNA interference-based
silencing, 80-90% and 70-80% depletions of TIA1 and TIAR
proteins, respectively (Figure 1A) were achieved 72 h after
transfection, thus in agreement with previous observations
[10]. By contrast, α-tubulin protein (Figure 1A) was used
as control of siRNA specificity, and its expression level was
not significantly affected by gene interference approach.
To test the microRNA (miRNA) expression profiles
resulting from the reduction of TIA1 and TIAR protein
levels, the differences in global miRNA expression patterns
in control and TIA1/TIAR-depleted HeLa cells were deter-
mined by means of a miRCURY™ LNA Array with specific
probes for simultaneous analysis of at least 600 different
miRNAs. After having passed sample QC on the Bioa-
nalyzer2100 and RNA measurement on the Nanodrop
instrument, the samples were labelled using the miR-
CURY™ Hy3™/Hy5™ labelling kit and hybridized on the
miRCURY™ LNA Array (v.8.1) (Figure 1B). Analysis of
the scanned slides showed that the labelling was suc-
cessful as all capture probes for the control spike-in
oligo nucleotides produced signals in the expected range.
The quantified signals were normalized using the global
Lowess (Locally WEighted Scatterplot Smoothing) regres-
sion algorithm, which we have found produces the best
within-slide normalization to minimize the intensity-
dependent differences between the dyes (Figure 1B). The
positive effect of this normalization is illustrated in 3
different plots for each experimental conditions analyzed
(Additional file 1). It is interesting to note the high repro-
ducibility of individual miRNA expression levels and their
correlation across the different miRNA pools (Additional
file 1). On the other hand, an appropriate statistical test
analysis was made using a linear model (as implemented in
Figure 1 Small interfering RNA (siRNA)-mediated depletion of TIA proteins. (A) Western blot analysis of HeLa cell lysates prepared 72 h
after transfection with siRNAs against control (C; lanes 1, 3 and 5) and TIA1 plus TIAR (lanes 2, 4 and 6). The blot was probed with antibodies
against TIA1, TIAR, and α-tubulin proteins, as indicated. Molecular weight markers and the identities of protein bands are shown. (B) A schematic
representation depicting the miRNA array strategy used in this study. The preparation of the RNA samples from control and TIA-depleted HeLa
cells, labeling of above RNA samples with Hy3 and Hy5 dyes, hybridization and analyses of the resulting miRNA profiles are illustrated.
Sánchez-Jiménez et al. BMC Molecular Biology 2013, 14:4 Page 4 of 16
http://www.biomedcentral.com/1471-2199/14/4the limma R/Biocounductor package) to compare miRNA
expression patterns for three two-color arrays performed
from three independent biological replicates (Figure 1 and
Additional file 1).
As shown in Table 1, depletion of TIA-proteins resulted
in significantly altered miRNA expression profiling. The
expression level of 29 out of 600 miRNAs was found to
more than double when comparing channels Hy5 and
Hy3. The genome-wide profiling analysis identified 17
miRNAs and 12 putative in-silico miRNAs (identified as
miRPlus). These were the well-established miRNAs:
miR-197-3p, miR-210, miR-373-5p, miR-492, miR-498,
miR-503-5p, miR-572, miR-586, miR-612, miR-615-3p,
miR-623, miR-625-5p, miR-638, miR-658, miR-663a, miR-
671-5p and miR-769-3p, which were differentially up-
regulated at least 2-fold (FDR<0.0001). The identified
miRPlus sequences were in licensed human sequences;
now a great number of these sequences have beenannotated in the corresponding miRNA database. This
information is available in Table 1. Regarding the differen-
tially expressed miRPlus in our experimental conditions, an
update of these miRPlus sequences in the miRBase 18 indi-
cates that miRPlus-17836 is miR-30b-3p, miRPlus-17864 is
miR-744-5p, miRPlus-17867 is miR-203a, miRPlus-17877
and miRPlus-17960 are miR-483-5p, miRPlus-17878 is
miR-193a-5p, miRPlus-17942 is miR-125a-3p, miRPlus-
17950 is miR-371-5p and miRPlus-17961 is miR-629-5p
(Table 1). The remaining miRPlus sequences have not
been yet assigned to the putative specific miRNAs
(Additional file 2).
To validate previous results on identified miRNAs and
their relative expression levels, four up-regulated and two
unchanged miRNAs were confirmed by TaqMan reverse
transcription and polymerase chain reaction (QPCR) ana-
lyses. As shown in Figure 2, the results obtained by quanti-
tative amplification were fully comparable and the relative
Table 1 MicroRNA expression profiling in TIA-depleted HeLa cells
Fold change pval (LiMMA) FDR (LiMMA) miRNA ID miRNA ID update
2.21 4.13E-06 8.26E-05 hsa-miR-197_MM2 hsa-miR-197-3p
3.84 5.00E-07 1.70E-05 hsa-miR-210 -
2.3 4.84E-06 9.38E-05 hsa-miR-373* hsa-miR-373-5p
2.75 3.78E-06 7.77E-05 hsa-miR-492 -
2.79 1.38E-06 3.55E-05 hsa-miR-498 -
2.5 5.22E-06 9.89E-05 hsa-miR-503 hsa-miR-503-5p
4.29 1.00E-07 4.05E-06 hsa-miR-572 -
3.78 3.60E-07 1.27E-05 hsa-miR-586 -
2.24 5.01E-06 9.59E-05 hsa-miR-612 -
2.82 4.50E-06 8.81E-05 hsa-miR-615 hsa-miR-615-3p
3.18 1.91E-06 4.50E-05 hsa-miR-623 -
2.84 1.23E-06 3.31E-05 hsa-miR-625 hsa-miR-625-5p
2.11 3.63E-06 7.54E-05 hsa-miR-638 -
2.44 1.64E-06 3.96E-05 hsa-miR-658 -
3.61 2.57E-06 5.63E-05 hsa-miR-663 hsa-miR-663a
2.23 2.75E-06 5.96E-05 hsa-miR-671 hsa-miR-671-5p
3.65 3.18E-06 6.70E-05 hsa-miR-769-3p -
3.44 2.60E-07 9.88E-06 miRPlus_17832 n.d.
2.73 9.60E-07 2.77E-05 miRPlus_17836 hsa-miR-30b-3p
4.38 5.70E-07 1.91E-05 miRPlus_17856 n.d.
3.34 2.26E-06 5.13E-05 miRPlus_17864 hsa-miR-744-5p
2.5 2.91E-06 6.23E-05 miRPlus_17867 hsa-miR-203a
2.7 6.30E-07 2.04E-05 miRPlus_17877/17960 hsa-miR-483-5p
2.33 4.69E-06 9.13E-05 miRPlus_17878 hsa-miR-193a-5p
2.84 1.87E-06 4.43E-05 miRPlus_17881 n.d.
3.63 5.50E-07 1.85E-05 miRPlus_17890 n.d.
3.3 2.16E-06 4.94E-05 miRPlus_17942 hsa-miR-125a-3p
2.15 2.85E-06 6.14E-05 miRPlus_17950 hsa-miR-371-5p
2.6 1.34E-06 3.45E-05 miRPlus_17961 hsa-miR-629-5p
miRNA cluster defining a signature of up-regulated miRNAs in TIA-depleted HeLa cells. The microarray data were analyzed by the limma R method. Fold is an
average measure of the fold change in differential expression and the false discovery rate (FDR) indicates the expected percentage of false positives (FDR < 0.0001).
miRNA ID update are miRNAs and miRPlus renamed in agreement with miRBase 18 database. n.d. means non-determined.
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the data detected by hybridization in the corresponding
microarrays (compare Table 1 and Figure 2).
As a first attempt to understand the relevance of 29 dif-
ferentially up-regulated miRNAs, in silico methods for pre-
dicting human miRNA target genes were used (Figure 3).
The potential target genes were identified by searching the
TargetScan, PicTar and miRBD databases [25-28]. By com-
paring and selecting alone non-repeated target genes, 2683
miRNA target genes were identified (Additional file 3). All
these potential target genes were tested using computer
tool GeneCodis3 [20,21] to elucidate the biological pro-
cesses and cellular pathways assigned using Gene Ontology
(GO) and Kyoto Encyclopedia of Genes and Genomes
(KEGG) database analyses (Figure 3 and Additional file 3).A total of 253 biological processes from GO database and
50 cellular pathways from KEGG categories were estimated
with a significance hypergeometric test (corrected hyper-
geometric p value < 0.01). Target genes corresponding
to the biological processes from GO categories were
mainly involved in regulation of DNA-dependent tran-
scription, signal transduction, multicellular organismal
development, positive/negative regulation of transcrip-
tion from RNA polymerase II promoter, cell adhesion,
transmembrane transport, apoptotic process and ner-
vous system development (Table 2 and Additional file
3). In addition, target genes associated to the main bio-
logical pathways were also identified using KEGG data-
base involving pathways in cancer, MAPK signalling
pathway, focal adhesion, endocytosis, regulation of
Figure 2 Validation of miRNA array-predicted changes by quantitative RT-PCR (QPCR). Quantitative miRNA expression analysis was carried
out using TaqMan probes by QPCR. The represented values were normalized and expressed relative to control values (whose value was fixed
arbitrarily to 1) as ratios and are means ± SD (n = 2).
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ligand-receptor interaction, glutamatergic synapse, ubiqui-
tin mediated proteolysis and tuberculosis (Table 2 and
Additional file 3). Collectively, these results suggest that
TIA-protein depletion promotes the induction of a miRNAFigure 3 Prediction of potential and experimental target genes assoc
Integrative analyses of potential target genes and miRNAs regulated in TIA
software tools (see corresponding section in Methods). Diagrams depicting
(Additional file 3) by TIA silencing are shown. Venn diagram depicting the
(highlighted in gray) associated to miRNAs and experimentally defined diff
cells lacking TIA proteins. The Gene Ontology (GO) and Kyoto Encyclopedia
using software programmes provided by GenCodis3.signature which may directly and indirectly contribute to
the establishment of the observed cellular phenotypes in
TIA-deficient HeLa cells [10].
On the other hand, the collection of differentially expressed
genes previously identified by expression microarray Humaniated with up-regulated miRNAs in TIA-depleted HeLa cells.
-depleted HeLa cells using TargetScan 5.2, PicTar-Vert and miRDB
the number of potential target genes and up-regulated miRNAs
numbers of genes that were intersected among putative target genes
erentially expressed genes (see additional data files in [10]) in HeLa
of Genes and Genomes (KEGG) database analyses were conducted
Table 2 Top ten biological processes and pathways associated to up-regulated miRNAs in TIA-depleted HeLa cells
Term Description Number of genes p-value
GO
GO:0006355 Regulation of transcription, DNA-dependent 269 2.49E-33
GO:0007165 Signal transduction 188 1.00E-18
GO:0007275 Multicellular organismal development 151 5.17E14
GO:0045944 Positive regulation of transcription from RNA pol II promoter 124 2.69E-21
GO:0007155 Cell adhesion 103 4.06E-12
GO:0055085 Transmembrane transport 102 5.89E-08
GO:0045893 Positive regulation of transcription, DNA-dependent 96 5.89E-14
GO:0006915 Apoptotic process 96 4.13E-07
GO:0000122 Negative regulation of transcription from RNA pol II promoter 95 4.66E-17
GO:0007399 Nervous system development 93 1.98E-16
KEGG
Kegg:05200 Pathways in cancer 68 5.72E-11
Kegg:04010 MAPK signaling pathway 58 3.68E-08
Kegg:04510 Focal adhesion 49 2.75E-08
Kegg:04144 Endocytosis 46 7.60E-07
Kegg:04810 Regulation of actin cytoskeleton 44 1.48E-04
Kegg:04310 Wnt signaling pathway 37 3.88E-05
Kegg:04080 Neuroactive ligand-receptor interaction 35 9.43E-04
Kegg:04724 Glutamatergic synapse 32 2.34E04
Kegg:04120 Ubiquitin mediated proteolysis 31 5.96E-03
Kegg:05152 Tuberculosis 28 1.17E-04
Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases analysis were carried out using GeneCodis3 software. The categories were
ranked on their numbers of associated genes and the ten with the highest number of genes are shown.
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cells [10] were intersected with potential target genes identi-
fied using in silico target prediction tools. The results show
that only 7 out of 68 (10%) up- and 71 out of 328 (22%)
down-regulated genes were shared (Figure 3 and Table 3).
GO and KEGG database analyses were independently per-
formed for up- and down-regulated genes with GeneCodis3
software. The results suggest that the enrichment functional
categories (p < 0.05) are related with signal transduction,
innate immune response and response to interleukin-1 for
up-regulated genes and glomerular basement membrane
development for down-regulated genes. Further, cellular
pathways of neuroactive lingand-receptor interaction and
apoptosis were associated to up-regulated genes, whereas
endocytosis and lysosomes were linked to down-regulated
genes (Table 4). Taken together, these results suggest that
at least a fraction (40%) of the up-regulated miRNAs (12
out of 30) could be contributing to the establishment of
differential expression profiles associated to the HeLa cells
lacking TIA proteins.
Based on above observations an interesting question
emerges: why should many specific genes be up- or down-
regulated by induced miRNAs in TIA-depleted HeLa cells?
A simple answer to this question might be that thesemRNAs or their precursors (pre-mRNAs) are targeted by
TIA proteins through one or multiple layers to exert the
control of their gene expression; thus, these regulators can
act as multifunctional RNA binding proteins (see refer-
ences included in Background). To approach this issue,
the experimental profiles of the binding patterns of TIA
proteins (i.e., the RNA map corresponding to TIA proteins)
at the up- or down-regulated pre-mRNAs (Figure 4 and
Table 3) were examined using the iCLIP database of TIA
proteins kindly provided by Jernej Ule’s laboratory [8]. For
example, as shown in Figure 4 and in Table 3, the pre-
mRNAs analyzed show multiple sequence sites located
across the full-length pre-mRNAs, both exons and introns,
and which we have classified as genes with either low (+),
medium (++) or high (+++) density of TIA binding sites.
The greatest relevance of this observation is the fact that
the density of binding sites on these pre-mRNAs is found
in both up- and down-regulated genes and located with
frequency on the last exons of these pre-mRNAs and par-
ticularly on the sequences located at the 30 untranslated
regions of the mature mRNAs. In this regard, it is reason-
able to think that the existence of a feedback loop that
represses the expression of many genes, which could be
activated in the absence of TIA proteins, for example at
Table 3 Intersection between potential and experimentally defined target genes related to miRNAs in TIA-depleted
HeLa cells
Gene symbol Description Associated miRNA TIA-iCLIP
Up-regulated genes
CNR1 Cannabinoid receptor 1 (brain) miR-30b-3p +
EIF4A2 Eukaryotic translation initiation factor 4A, isoform 2 miR-586 +++
EREG Epiregulin miR-586 +
F2RL2 Coagulation factor II (thrombin) receptor-like 2 miR-30b-3p +
IL1R1 Interleukin 1 receptor, type I miR-498 ++
IRAK2 Interleukin-1 receptor-associated kinase 2 miR-503-5p ++
SELI Selenoprotein I miR-197-3p ++
Down-regulated
genes
ACADSB Acyl-Coenzyme A dehydrogenase, short/branched chain miR-203 ++
ACOX1 Acyl-Coenzyme A oxidase 1, palmitoyl miR-373-5p ++
ALS2CR4 Amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 4 miR-203 +++
ANKH Ankylosis, progressive homolog (mouse) miR-203 +++
AP1S2 Adaptor-related protein complex 1, sigma 2 subunit miR-203 ++
AP2B1 Adaptor-related protein complex 2, beta 1 subunit miR-203 +++
APPBP2 Amyloid beta precursor protein (cytoplasmic tail) binding protein 2 miR-612 ++
BBS1 Bardet-Biedl syndrome 1 miR-612 +
BRIP1 BRCA1 interacting protein C-terminal helicase 1 miR-373-5p +
C16orf72 Chromosome 16 open reading frame 72 miR-671-5p +++
C18orf54 Chromosome 18 open reading frame 54 miR-625-5p ++
C1orf96 Chromosome 1 open reading frame 96 miR-373-5p ++
C20orf108 Chromosome 20 open reading frame 108 miR-30b-3p +
CCDC50 Coiled-coil domain containing 50 miR-203 +
CENPH Centromere protein H miR-612 +
CLCC1 Chloride channel CLIC-like 1 miR-373-5p and 30b-3p ++
COL4A4 Collagen, type IV, alpha 4 miR-203 +++
CTDSPL2 CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) small phosphatase
like 2
miR-203 +++
CTSC Cathepsin C miR-203 ++
DAB2 Disabled homolog 2, mitogen-responsive phosphoprotein (Drosophila) miR-203 +++
DDIT4 DNA-damage-inducible transcript 4 miR-30b-3p ++
EEF1A1 Eukaryotic translation elongation factor 1 alpha 1 miR-373-5p +
EIF4EBP2 Eukaryotic translation initiation factor 4E binding protein 2 miR-373-5p ++
ELMOD2 ELMO/CED-12 domain containing 2 miR-30b-3p ++
EPHA7 EPH receptor A7 miR-503-5p +++
FAM129A Family with sequence similarity 129, member A miR-373-5p and 586 ++
FBXO9 F-box protein 9 miR-203 ++
IQCE IQ motif containing E miT-483-5p +
KCTD12 Potassium channel tetramerisation domain containing 12 miR-373-5p and 586 +
KLF9 Kruppel-like factor 9 miR-373-5p ++
KRIT1 KRIT1, ankyrin repeat containing miR-373-5p +
LAMP2 Lysosomal-associated membrane protein 2 miR-373-5p ++
MCM4 Minichromosome maintenance complex component 4 miR-373-5p ++
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Table 3 Intersection between potential and experimentally defined target genes related to miRNAs in TIA-depleted
HeLa cells (Continued)
MECP2 Methyl CpG binding protein 2 (Rett syndrome) miR-203 +
MIB1 Mindbomb homolog 1 (Drosophila) miR-373-5p, 503 and
203
++
MOBKL2B MOB1, Mps One Binder kinase activator-like 2B (yeast) miR-503-5p and 203 +++
MTAP Methylthioadenosine phosphorylase miR-125a-3p ++
MTHFD2L Methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2-like miR-373-5p ++
NAV1 Neuron navigator 1 miR-503-5p ++
NDRG3 NDRG family member 3 miR-203 ++
NDST1 N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 1 miR-30b-3p +
NHLRC2 NHL repeat containing 2 miR-373-5p ++
NID1 Nidogen 1 miR-30b-3p ++
PAWR PRKC, apoptosis, WT1, regulator miR-30b-3p +++
PCGF6 Polycomb group ring finger 6 miR-203 +
PDE1A Phosphodiesterase 1A, calmodulin-dependent miR-373-5p +++
PGM2 Phosphoglucomutase 2 miR-498 +++
PLD1 Phospholipase D1, phosphatidylcholine-specific miR-203 +++
RAB22A RAB22A, member RAS oncogene family miR-498 ++
RBM8A RNA binding motif protein 8A miR-373-5p +
RECK Reversion-inducing-cysteine-rich protein with kazal motifs miR-503-5p ++
RGC32 Regulator of cell cycle miR-30b-5p ++
SFPQ Splicing factor proline/glutamine-rich (polypyrimidine tract binding protein
associated)
miR-586 ++
SGPL1 Sphingosine-1-phosphate lyase 1 miR-373-5p ++
SLC12A2 Solute carrier family 12 (sodium/potassium/chloride transporters), member 2 miR-503-5p, 586 and
203
+
SLC35B3 Solute carrier family 35, member B3 miR-203 ++
SNAPC3 Small nuclear RNA activating complex, polypeptide 3, 50kDa miR-373-5p and 671 +++
STXBP4 Syntaxin binding protein 4 miR-625-5p +
SUDS3 Suppressor of defective silencing 3 homolog (S. cerevisiae) miR-203 +++
SYNC1 Syncoilin, intermediate filament 1 miR-203 ++
TFDP2 Transcription factor Dp-2 (E2F dimerization partner 2) miR-30b-3p and 203 +++
TIA1 TIA1 cytotoxic granule-associated RNA binding protein miR-30b3p +++
TNFRSF19 Tumor necrosis factor receptor superfamily, member 19 miR-125a-3p ++
TNRC6B Trinucleotide repeat containing 6B miR-503-5p, 586 and
203
++
TSEN2 tRNA splicing endonuclease 2 homolog (S. cerevisiae) miR-197-3p +
VAMP1 Vesicle-associated membrane protein 1 (synaptobrevin 1) miR-203 ++
VGLL3 Vestigial like 3 (Drosophila) miR-373-5p ++
VPS13A Vacuolar protein sorting 13 homolog A (S. cerevisiae) miR-586 ++
WDFY3 WD repeat and FYVE domain containing 3 miR-203 +
ZBTB44 Zinc finger and BTB domain containing 44 miR-203 ++
ZNF169 Zinc finger protein 169 miR-125a-3p ++
Gene cluster defining a molecular signature of up- (highlighted in red in Figure 3) and down-regulated (highlighted in green in Figure 3) genes linked to up-
regulated miRNAs in TIA-depleted HeLa cells. Gene symbol, gene title as description and associated miRNAs are indicated. Estimation of the density of binding
sites of TIA proteins on up- and down-regulated target genes by iCLIP analysis is shown. The relative quantification estimated as low (+), medium (++) and high
(+++) density is indicated.
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Table 4 Biological processes and pathways linked to experimentally defined and differentially expressed genes in TIA-
depleted HeLa cells
Categories enriched in Description Number of genes Gene symbol p-value
Up-regulated genes
GO term
GO:0070555 Response to interleukin-1 2 IL1R1, IRAK2 6.21E-04
GO:0045087 Innate immune response 2 IL1R1, IRAK2 6,88E-03
GO:0007165 Signal transduction 2 IL1R1, IRAK2 2,88E-02
KEGG term
Kegg:04080 Neuroactive ligand-receptor interaction 2 CNR1, F2RL2 6.88E-03
Kegg:04210 Apoptosis 2 IL1R1, IRAK2 1.43E-03
Down-regulated genes
GO term
GO:0032836 Glomerular basement membrane development 2 COL4A4, NID1 1.09E-02
KEGG term
Kegg:04144 Endocytosis 4 RAB22A, AP2B1, DAB2, PLD1 3.23E-02
Kegg:04142 Lysosome 3 CTSC, AP1S2, LAMP2 4.77E-02
Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases analysis were carried out using GeneCodis3 software.
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translational activation), to dampen its expression in order
to promote or counteract the cellular phenotypes asso-
ciated to the absence of the TIA proteins.
During the last decade, much progress has been made
in the understanding of network topology and the rele-
vance and properties of its basic modules. In this study,
we analyze and assess module networks inferred from
both miRNAs and gene expression data using a bioinfor-
matic tool as CytoScape [32]. By matching expressed
miRNAs and experimentally defined up- and down-
regulated genes in TIA-depleted HeLa cells, a putative
regulatory network of TIA-associated genes and miRNAs
was constructed. Based on the number of potential gene
interactions with single miRNAs, both up- and down-
expressed genes regulating TIA-mediated differential
expression were connected (Figure 5). This network draws
a cellular scenario where the reduction of TIA proteins
could lead to molecular responses mediated by individual
miRNAs. Such a computational approach, starting from
expression data alone, can be helpful in the future process
of identification of the function of these miRNAs by sug-
gesting modules of co-expressed genes in which they
could play a regulatory role.
Discussion
Current data suggest that a significant portion of the
information containing the human genome is regulated
by miRNAs. These small RNAs recognize and regulate
target genes. In this regard, more than 60% of protein-
coding genes are predicted in silico as targets, based onconserved base-pairing between the 30- and 50-untranslated
regions (UTR) of the mRNA and the seed sequence of the
miRNAs [33] without considering putative target on coding
sequences. At present, near to 2,000 miRNAs have been
identified in the human genome and about 20-30% of
human genes are controlled by one or more miRNAs
[33-36]. Multiple lines of evidence indicate that they are
key regulators of numerous critical functions in develop-
ment and disease, including cancer. Many of them have
been reported to have molecular features and act either
as tumour suppressors or oncogenes [33-35]. The changes
in miRNA signature identified in this study might directly
and indirectly function as encouraging/counteracting mech-
anism of biological processes and cellular pathways to
promote/attenuate the inflammatory, angiogenic and pro-
liferative responses linked to TIA-depleted HeLa cells [10].
Given that many target genes associated with the iden-
tified up-regulated miRNAs are down-regulated (Table 3)
in TIA-depleted HeLa cells [10], from a mechanistic
viewpoint our results indicate that mRNA abundance in
most targeted genes was somewhat affected by miRNAs,
thus suggesting that, for a substantial number of genes
regulated by TIA-protein absence, destabilization of mRNA
may be the main mechanism of protein repression by these
miRNA-mediated regulators. This observation agrees with
a recent study, suggesting that mammalian miRNAs pre-
dominantly reduce target mRNA levels [34]. However,
some miRNAs such as miR-744 enhances cyclin B1 mRNA
expression through a novel mechanism. miRNA positively-
regulates gene expression by targeting promoter elements;
this phenomenon is known as RNA activation [37]. In this
Figure 4 RNA map of TIA proteins in targeted pre-mRNAs related with miRNAs in TIA-deficient HeLa cells. (A and B) Profiles of
experimental crosslink sites of TIA1 and TIAR proteins (adapted from TIA-iCLIP analysis [8]) on up- (A) and down-regulated (B) pre-mRNAs in TIA-
depleted HeLa cells. Representative examples of up- (A) and down-regulated (B) genes with low (+), medium (++) and high (+++) density of TIA
binding sites are shown. The bar graph in each panel indicates the number of cDNAs that identified each crosslink site.
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be operating in the up-regulation observed for seven target
genes associated with the up-regulated miRNAs (Table 3).
Furthermore, miRNAs do not only regulate the expression
of protein-encoding genes but also other miRNAs: for in-
stance, let-7a controls the expression of important epigen-
etic regulators, including epigenetic miRNA regulatory
circuits, and organizes the whole gene expression profile
[38]. On the other hand, there are miRNA-target interac-
tions that involve multiple sites for a given target and
confer much stronger repression. More often, different
miRNAs work together to co-target a given mRNA, there-
fore their combined repressive effect greatly exceeds the
individual contributions [34-36]. Both regulatory situa-
tions are observed in the down-regulated genes asso-
ciated to up-regulated miRNAs in TIA-depleted HeLa
cells (Table 3). This suggests that clusters of miRNAs
can play a more prominent role than only reinforcingthe expression patterns dictated by transcriptome dynam-
ics. The existence of interactions among these regulators
and the interactions between their regulatees suggests that
these miRNAs generate networks that modulate antagon-
istic cellular responses, such as apoptosis or cell prolifera-
tion induction and/or repression. Our set of data indicates
that the action of miRNAs could potentially be another
important mechanism in the regulation of gene expression
and some gene regulatory networks mediated by TIA pro-
teins. These observations thus suggest the existence of
feedback mechanisms that promote miRNA expression,
which might therefore contribute to dampen the pheno-
types observed in TIA-lacking HeLa cells. A type 2 in-
coherent feedforward loop [39] may contribute to the
repression model between TIA proteins, target genes and
associated miRNAs. This feedforward loop could reinforce
the functional role of TIA proteins as repressors of inflam-
matory, angiogenic, and proliferative responses (Figure 6).
Figure 5 Regulatory network of up-regulated miRNAs and intersection with target genes associated with TIA-depleted HeLa cells.
Elongated circles represent differentially expressed miRNAs and genes (red and brown- increased, green- decreased). Lines represent regulatory
relations between differentially expressed miRNAs and genes.
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could be related to miRNA-mediated gene expression
fluctuations and, more faithfully, to signal outcomes in the
context of specific regulatory networks. This suggest that
miRNAs can strenghten transcriptome patterns by buffer-
ing the deleterious effects of some network states linked
to random fluctuations in gene expression program, in
agreement with previous findings [25]. Since little experi-
mental information is available on potential target genes
and miRNA cluster identified in our study and we have
not experimentally carried out analysis of gain- and loss-
of function, we used experimental data on miRNA func-
tion to understand the potential implication and relevance
of these miRNAs in the development and progression of
(patho)-physiological conditions. For example, miRNA-30b has been implicated in angiogenesis [40], TRAIL-
induced apoptosis in glioma cells [41] and oral squa-
mous cell cancers [42]. miR-193a-5p targets YY1-APC
regulatory axis in human endometrioid endometrial
adenocarcinoma [43]. miR-203 participates in a regulatory
network that modulates epithelial to mesenchymal transi-
tion [44] as well as to promote suppression immune [45].
miR-210 is induced under hypoxia and works as a iron
sensor to stimulate cell proliferation and promote cell sur-
vival in the hypoxic region within tumor [46-48]. Further,
this miRNA modulates the mitochondrial functioning
and metabolism [49,50], represses FGFRL1 and E2F3 ex-
pression, which inhibits cell apoptosis in hypoxia response
[51,52], predicts poor survival in patients with breast
cancer [53] and activates notch signalling pathway in
Figure 6 An overview summarizing the cellular and molecular
events associated to the reduction of TIA proteins. The
availability of TIA proteins could be contributing to a regulatory loop
mediated by miRNAs to modulate target gene expression related to
inflammatory, angiogenic and/or proliferative responses/phenotypes
in HeLa cells.
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http://www.biomedcentral.com/1471-2199/14/4angiogenesis [54]. In addition, miR-371-5p is increased
in gastric cancer [55] and miR-373 functions as an onco-
gene in hepatocellular carcinoma given that is a new regu-
lator of protein phosphatase 6 [56], an repressor of the
large tumor suppressor homolog 2 [57] and promotestumor invasion and metastasis in testis cancer [58,59].
Further, both miRNA-210 and miRNA-373 participate
in the gene expression control of DNA repair in hyp-
oxic stress [60]. miRNA-492 and miRNA-498 are highly
expressed and regulate metastatic functions in hepatoblas-
toma, rectal cancer, adenocarcinoma and retinoblastoma
[61-64]. In addition, miR-503 is induced in angiogenesis,
down-regulates CUGBP1 and modulates metastatic func-
tion in hepatocellular cancer cell [65-68]. miRNA-572
has been involved in chronic lymphocytic leukaemia
via targeting anti-apoptotic genes [69,70]. miRNA-586 is
up-regulated in colorectal cancer [71]. miRNA-615-3p
dysregulates CDKN2A, NF2 and JUN in malignant meso-
thelioma [72] and enhances the phagocytic capacity of
splenic macrophages [73]. miRNA-625 promotes invasion
and metastasis of gastric cancer by targeting ILK [74].
miR-629 is associated to lung cancer by targeting NBS1 [75].
miRNA-638 and miR-658 are up-regulated in cell trans-
formation and human gastric cancer [76,77]. In addition,
other miRNAs show a great potential as activators of cell
proliferation/transformation phenotypes; for example miRNA-
663 functions as an oncogene promoting tumorigenesis
by targeting p21(WAF1/CIP1), VEGF, JunB, JunD and
TGFB1 genes [78-80] and plays also a role in inflam-
matory response of endothelial cells [81]. miRNA 671 reg-
ulates CD44 inducing metastasis by regulating extracellular
matrix functions [82] as well as miRNA-dependent gene
silencing involving Ago2-mediated cleavage of a circular
antisense RNA [83]. miRNA-744 up-regulates Cyclin B1
expression [37] and down-regulates Transforming Growth
Factor Beta-1 expression [84]. On the other hand, other
miRNAs identified in our study have bipolar features and
putatively antagonistic behaviours as opposite regulators
acting either positively or negatively under specific bio-
logical programmes. In this regards, there are at least 2
miRNAs showing functions to repress proliferation, angio-
genesis and transformation phenotypes. This is the case
of miRNA-483-5p, which suppresses the proliferation of
glioma cells via directly targeting ERK1 [85] and angio-
genesis in vitro by targeting serum response factor [86].
However, microRNA-483-5p and miRNA-195 have been
identified as predictors of poor prognosis in adrenocortical
cancer [87]. miR-125a-3p is down-regulated in non-small
cell lung cancer, having inverse effects on invasion and mi-
gration of lung cancer cells [88]. This miRNA is a potent
prognostic marker in gastric cancer [89]. Collectively,
the miRNA expression profiling identified in this study
has important aftermath in tumorigenesis and could
contribute/repress to the development of cell prolifera-
tion, angiogenesis, transformation phenotypes, because
individual miRNAs are associated with diagnosis, progno-
sis and treatment efficacy linked to the biology of human
tumors. Therefore, these miRNAs can target to onco-
genes or tumor suppressor genes (also they can even
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promotion or inhibition of tumorigenesis and cancer
progression, thus being able to confer robustness to
these pathological phenotypes.
In summary, our findings suggest that expression changes
in individual miRNAs in TIA-depleted HeLa cells could
directly or indirectly impact on biological processes and
signaling pathways to favour cell phenotypes associated to
the down-regulation of TIA proteins (Figure 6). Further,
our observations suggest that some of the identified miR-
NAs are consistent with an adaptive response aimed at
attenuating the inflammatory, angiogenic, and proliferative
responses developed in TIA-protein absence. Therefore,
cross talk between regulatory mechanisms that promote
increased/reduced expression of miRNA-mediated genes
may contribute to modify the relative expression levels of
the mRNAs associated with TIA-lacking HeLa cells. Based
on this integrative analysis, our results provide a promin-
ent stand for future approaches aimed at characterizing
the role of specific miRNAs in TIA-mediated gene expres-
sion regulation.
Conclusions
Gene expression profiling approaches have improved our
understanding on how the human transcriptome dynam-
ics orchestrates global responses at molecular level to an-
swer to changing environmental challenges. Our study
identifies a human miRNA collection that displays signifi-
cant changes in the transient absence of TIA proteins in
HeLa cells. The most prominent changes are linked to the
up-regulation of miR-30b-3p, miR125a-3p, miR-193a-5p,
miR-197-3p, miR-203a, miR-210, miR-371-5p, miR-373-5p,
miR-483-5p, miR-492, miR-498, miR-503-5p, miR-572, miR-
586, miR-612, miR-615-3p, miR-623, miR-625-5p, miR-629-
5p, miR-638, miR-658, miR-663a, miR-671-5p, miR-769-3p
and miR-744-5p. The integration of the identified miRNAs
with the potential target genes and previous gene expression
data under the same experimental conditions revealed en-
richment of biological processes and signaling pathways
controlling relevant members of the pathways associated
to the oncogenesis. Down-regulation of these cellular com-
ponents may contribute to establish the inflammatory,
angiogenic, and proliferative responses previously described
in TIA protein-lacking HeLa cells. Therefore, our results
are consistent with the existence of regulatory networks
that generate correlated expressions, commonly involving
miRNAs [33,90]. This regulatory architecture may increase
the fidelity of inhibition of the downstream components by
acting on them redundantly. In other words, a transient
loss of TIA proteins can be partially compensated for by
the adaptive presence of specific miRNAs. Collectively,
these findings suggest that TIA proteins can act as
multifunctional regulators to provide a novel meeting
point between the mechanisms for cross-talking amongconcerted post-transcriptional regulatory layers that co-
ordinate complex cellular responses.
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